De Novo Donor-Specific HLA Antibodies Developing Early or Late after Transplant Are Associated with the Same Risk of Graft Damage and Loss in Nonsensitized Kidney Recipients
Table 1
Clinical features of the patients analysed and according to the date of de novo donor specific HLA antibody (dnDSA) onset.
Variables
All patients ()
All patients with dnDSAs ()
Patients with dnDSAs occurring within year 1 ()
Patients with dnDSAs occurring beyond year 1 ()
value
Characteristics at Tx
Recipient
Male sex
69 (60.5%)
27 (69%)
12 (80%)
15 (62.5%)
0.30
Age
13.4
13.20
10.27
15.03
<0.05
Donor
Male sex
70 (61.4%)
25 (64%)
11 (73%)
14 (58%)
0.50
Age
17.2
13.15
11.53
14.17
0.46
Deceased
97 (85%)
36 (92%)
14 (93%)
22 (92%)
1
Transplantation
Number of total HLA A, B mismatches
2.36
2.56
2.47
2.63
0.70
Number of total HLA DR, DQ mismatches
1.61
1.85
2.00
1.75
0.42
Number of total HLA A, B, DR, DQ mismatches
3.97
4.41
4.47
4.38
0.81
Characteristics after Tx
CyA in maintenance IS
66 (58%)
30 (77%)
10 (67%)
20 (83%)
0.27
Delayed graft function
13 (11%)
4 (10%)
1 (7%)
3 (12%)
0.50
Acute T cell-mediated rejection
18 (16%)
8 (20%)
2 (13%)
6 (25%)
0.45
eGFR < 60 at 1 year
14 (12%)
7 (18%)
1 (7%)
6 (25%)
0.21
AMR
21 (18%)
21 (54%)
7 (47%)
14 (58%)
0.52
Including borderline changes. Tx: transplantation; CyA: cyclosporin A; IS: maintenance immunosuppression; eGFR: estimated glomerular filtration rate (ml/min/1.73 m2).
